Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 May 1:19:695-703.
doi: 10.2147/CIA.S447272. eCollection 2024.

Assess the Outcomes of Transcatheter Aortic Valve Replacement in Bicuspid Valve with Mixed Disease versus Predominant Aortic Stenosis

Changjin Wang #  1 , Xiaolu Hu #  1   2 , Songyuan Luo #  1 , Yinghao Sun  1 , Bangyuan Yang  1 , Shengneng Zheng  3 , Jiaohua Chen  1 , Ming Fu  1 , Ruixin Fan  4 , Jie Li  1 , Jianfang Luo  1   2
Affiliations
Comparative Study

Assess the Outcomes of Transcatheter Aortic Valve Replacement in Bicuspid Valve with Mixed Disease versus Predominant Aortic Stenosis

Changjin Wang et al. Clin Interv Aging. .

Abstract

Purpose: In mixed aortic valve disease (MAVD), the results of transcatheter aortic valve replacement (TAVR) are conflicting. There is limited data on the outcomes of TAVR in patients with bicuspid aortic valve (BAV) and MAVD. The objective of this study is to compare outcomes after TAVR in BAV patients with MAVD and predominant aortic stenosis (PAS).

Patients and methods: Patients with BAV who underwent TAVR between January 2016 and April 2023 were included. The primary outcome was device success. The secondary endpoints were periprocedural mortality and other complications as defined by the Valve Academic Research Consortium-3 (VARC-3). Propensity score matching was used to minimize potential confounding.

Results: A total of 262 patients were included in this study, 83 of whom had MAVD. The median age was 72 years, and 55.7% were male. The baseline comorbidity risk files were comparable between the two groups. Patients with MAVD had more mitral regurgitation, tricuspid regurgitation and pulmonary hypertension, larger annular and left ventricular outflow tract dimensions, and more severe calcification than PAS. In the unmatched population, MAVD patients had similar device success rate (69.9% vs 79.9%, P=0.075) and 30-day mortality (3.6% vs 3.4%, P=1) compared to PAS. Propensity score matching resulted in 66 patient pairs. Device success rate were still comparable in the matched population. Other clinical outcomes, including stroke, bleeding (type 2-4), major vascular complications, acute kidney injury (stage 2-4) and permanent pacemaker implantation, were comparable between the two groups. Multivariable logistic regression analysis did not show MAVD to be an independent negative predictor of device success. At one year, survival was similar between patients with MAVD and those with PAS.

Conclusion: For the bicuspid valve, patients with MAVD had a more challenging anatomy. MAVD patients associated with comparable 30-day clinical outcomes after TAVR compared to PAS patients in patients with BAV.

Keywords: bicuspid aortic valve; device success; mixed aortic valve disease; propensity score match; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest in this work.

Figures

Figure 1
Figure 1
48 months survival in MAVD and PAS patients. (A) 48 months survival in the whole cohort; (B) 48 months survival in the propensity score matches cohort.
See this image and copyright information in PMC

References

    1. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609–1620. doi:10.1056/NEJMoa1514616 - DOI - PubMed
    1. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–2484. doi:10.1016/S0140-6736(15)60308-7 - DOI - PubMed
    1. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. J Am Coll Cardiol. 2021;77(9):1149–1161. doi:10.1016/j.jacc.2020.12.052 - DOI - PubMed
    1. Vincent F, Ternacle J, Denimal T, et al. Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Stenosis. Circulation. 2021;143(10):1043–1061. doi:10.1161/CIRCULATIONAHA.120.048048 - DOI - PubMed
    1. Forrest JK, Kaple RK, Ramlawi B, et al. Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Aortic Valves From the STS/ACC TVT Registry. JACC: Cardiovasc Interv. 2020;13(15):1749–1759. doi:10.1016/j.jcin.2020.03.022 - DOI - PubMed

Publication types